
Amylyx Pharma shares jump 54% on positive Phase 3 trial for avexitide reducing hypoglycemia.
Amylyx Pharmaceuticals' stock surged 54.43% after its drug avexitide showed positive Phase 3 trial results, cutting hypoglycemic events by 55% in post-bariatric patients. UBS set a $45 price target, implying a 36% upside from current levels. The stoc...


